Merck Announces Third-Quarter 2016 Dividend
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.46 per share of the company’s common stock for the third
quarter of 2016. Payment will be made on July 8, 2016 to shareholders of
record at the close of business on June 15, 2016.
About Merck
Language:
English
Contact:
...
Source: Merck.com - Corporate News - May 24, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Dividend MSD NYSE:MRK Source Type: news
Merck to Present at the UBS Global Healthcare Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Adam Schechter, executive vice president and
president, Global Human Health, Merck, is scheduled to present at the
UBS Global Healthcare Conference in New York on May 25, 2016 at 8:00
a.m. EDT.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors...
Source: Merck.com - Corporate News - May 24, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD UBS Source Type: news
Merck Announces FDA Accepts Samsung Bioepis’ Biologics License Application (BLA) for SB2 (Infliximab), an Investigational Biosimilar of Remicade
Dateline City:
KENILWORTH, N.J.
First BLA Filed by Samsung Bioepis as Part of Its Partnership with Merck
KENILWORTH, N.J. – Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) submitted by Samsung Bioepis Co., Ltd. for SB2 (infliximab), an investigational biosimilar candidate of Remicade.
Language:
English
...
Source: Merck.com - Corporate News - May 23, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to High-Quality Cancer Care in Underserved Communities in the United States
Dateline City:
KENILWORTH, N.J.
Merck Foundation Accepting Applications from Non-Profit Organizations
KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation announced today the launch of a new initiative, the Alliance
to Advance Patient-Centered Cancer Care (the Alliance), to support
programs aimed at improving timely access to patient-centered care and
reduce disparities in cancer care, especially for vulnerable and
underserved populations in the United States.
L...
Source: Merck.com - Corporate News - May 23, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK cancer Merck Foundation MSD Source Type: news
Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association
Dateline City:
KENILWORTH, N.J.
Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Also to Be Presented
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers will present data from clinical trials
of its investigational diabetes pipeline, JANUVIA®
(sitagliptin), and new real-world research in more than 20 scientific
data presentations at the ...
Source: Merck.com - Corporate News - May 12, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ADA Source Type: news
Merck Announces First-Quarter 2016 Financial Results
Dateline City:
KENILWORTH, N.J.
First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS Increased by 5 Percent to $0.89
Company Continues to Expect 2016 Full-Year GAAP EPS to be Between $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be Between $3.65 and $3.77
First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1 Percent, Including a 4 Percent Negative Impact from Foreign Exchange
Obtained FD...
Source: Merck.com - Corporate News - May 5, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD Source Type: news
Merck to Present at the Deutsche Bank 41st Annual Health Care Conference
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Adam Schechter, executive vice president and
president, Global Human Health, Merck, is scheduled to present at the
Deutsche Bank 41st Annual Health Care Conference in Boston on May 5,
2016 at 12:50 p.m. EDT.
Language:
English
Contact:
MerckMedia:La...
Source: Merck.com - Corporate News - May 4, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Deutsche Bank 41st Annual Health Care Conference MSD NYSE:MRK Source Type: news
Christina Applegate and Merck Urge Insomnia Sufferers to Learn “Why They’re So Awake”
Dateline City:
KENILWORTH, N.J.
Christina Applegate Shares Personal Struggle with Insomnia and Encourages Others to Educate Themselves about the Wake and Sleep Systems in the Brain
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy® Award-winning actress Christina Applegate to educate the millions of Americans struggling with insomnia. An insomnia sufferer for much of her adult life, Applegate is sharing her personal experience...
Source: Merck.com - Corporate News - April 28, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System
Dateline City:
MADISON, N.J.
Non-Invasive Device Helps Diagnose Bovine Respiratory Disease
MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United
States and Canada) today announced plans to acquire worldwide rights for
the Whisper® Veterinary Stethoscope System from
Minnesota-based Geissler Companies. The Whisper Veterinary Stethoscope
System is a Bovine Respiratory Disease (BRD) detection system which is
used to deter...
Source: Merck.com - Corporate News - April 19, 2016 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK MSD Whisper Source Type: news
Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is
proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an
important initiative to compare several new diagnostic tests for the
immune biomarker PD-L1 in non-small cell lung cancer (NSCLC).
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558An Phan, ...
Source: Merck.com - Corporate News - April 19, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Blueprint Project MSD Source Type: news
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
Dateline City:
KENILWORTH, N.J.
Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab),
the company’s anti-PD-1 therapy, for the treatment of patients w...
Source: Merck.com - Corporate News - April 18, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Hodgkin Lymphoma Keytruda MSD NYSE:MRK Source Type: news
Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from two Phase 3 clinical
trials evaluating ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg
tablets in chronic hepatitis C (HCV) patients with inherited blood
disorders (C-EDGE
IBLD) and in patients with a history of intravenous drug
use who are receiving opioid agonist therapy (C-EDGE
CO-STAR), respectively.
Language:
...
Source: Merck.com - Corporate News - April 16, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK International Liver Congress MSD ZEPATIER Source Type: news
Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Dateline City:
KENILWORTH, N.J.
Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress™ 2016
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from C-EDGE
Head-to-Head, the company’s comparative, Phase 3,
open-label clinical trial evaluating the efficacy and safety of...
Source: Merck.com - Corporate News - April 14, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK ZEPATIER Source Type: news
Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite sublingual allergy immunotherapy (SLIT) tablet.
Language:
English
read more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - April 12, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will hold its first-quarter 2016 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Thursday, May
5. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - April 8, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
